Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
The global market for colorectal cancer screening is expected to grow at a CAGR of 4.4% during the forecast period (2018-2023). The North American region holds the highest market share in colorectal cancer therapeutics and has been the dominant region globally for the colorectal cancer diagnostics and therapeutics market.
Increasing Incidence and Prevalence of Colorectal Cancer
Colorectal cancer (CRC) accounts for over 9% of all cancer incidences, and it is a major cause of morbidity and mortality throughout the world. CRC is the second most common cause of cancer-related deaths in the United States. Moreover, there is an increase in the number of colorectal cancer screening tests, such as CT colonography, double-contrast barium enema, and biopsy test, which are being used for the treatment of people, thereby, driving the market for global colorectal cancer therapeutics in the near future.
The other factors which also help in the growth of the market include technological advancements in radiology & chemotherapy, increasing cancer prevention initiatives, and
others.
High Costs of the Screening Associated with the Drugs
Many of the high-income countries, including the United Kingdom and the United States, are facing the challenges of providing care to an ever-increasing population of colorectal cancer patients, owing to expensive screening and treatment. The researchers found that the average annual out-of-pocket costs associated with a new cancer diagnosis were USD 2,116 for Medicaid beneficiaries. The financial burden varies among patients based on the clinical stage. Moreover, the biomarker tests, such as the multi-target stool DNA test, are more expensive than the FOBTs and come with relatively low specificity. The price for a cologuard test is more than that of traditional stool tests for CRC screening. All of these statistics show that the cost of these treatments is high due to which the market is restrained.
The other factor which is restraining the growth of the market is the inadequate healthcare access in developing countries and underdeveloped countries.
China and India Rapidly Growing
Geographically, North America holds the largest market share with respect to the demand and revenue. In 2017, based on the estimates by the American Cancer Society, 39,910 new rectal cancer cases and 95,520 new colon cancer cases were reported in the United States. These estimates show that the colorectal cancer is increasing its prevalence in the United States which is leading to the growth of the market. The Asia-Pacific is also expected to show a strong growth pattern in the coming years, with China and India showing a rapid progress.
Key Developments in the Market
• May 2017: Novigenix signed a distribution agreement with Dr. Risch Medical Laboratory to access the Swiss German market for colox, its blood based colorectal cancer test
Major Players: ABBOTT DIAGNOSTICS, NOVIGENIX, ALERE, BECKMAN COULTER, CLINICAL GENOMICS, COMPANION DX, EDP BIOTECH, EPIGENOMICS AG, SIEMENS HEALTHCARE, QUEST DIAGNOSTICS, METABIOMICS CORPORATION, AND VOLITION RX, amongst others.
Reasons to Purchase this Report
• Current and future colorectal cancer diagnostics and therapeutics market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• Analysis on the segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
Increasing Incidence and Prevalence of Colorectal Cancer
Colorectal cancer (CRC) accounts for over 9% of all cancer incidences, and it is a major cause of morbidity and mortality throughout the world. CRC is the second most common cause of cancer-related deaths in the United States. Moreover, there is an increase in the number of colorectal cancer screening tests, such as CT colonography, double-contrast barium enema, and biopsy test, which are being used for the treatment of people, thereby, driving the market for global colorectal cancer therapeutics in the near future.
The other factors which also help in the growth of the market include technological advancements in radiology & chemotherapy, increasing cancer prevention initiatives, and
others.
High Costs of the Screening Associated with the Drugs
Many of the high-income countries, including the United Kingdom and the United States, are facing the challenges of providing care to an ever-increasing population of colorectal cancer patients, owing to expensive screening and treatment. The researchers found that the average annual out-of-pocket costs associated with a new cancer diagnosis were USD 2,116 for Medicaid beneficiaries. The financial burden varies among patients based on the clinical stage. Moreover, the biomarker tests, such as the multi-target stool DNA test, are more expensive than the FOBTs and come with relatively low specificity. The price for a cologuard test is more than that of traditional stool tests for CRC screening. All of these statistics show that the cost of these treatments is high due to which the market is restrained.
The other factor which is restraining the growth of the market is the inadequate healthcare access in developing countries and underdeveloped countries.
China and India Rapidly Growing
Geographically, North America holds the largest market share with respect to the demand and revenue. In 2017, based on the estimates by the American Cancer Society, 39,910 new rectal cancer cases and 95,520 new colon cancer cases were reported in the United States. These estimates show that the colorectal cancer is increasing its prevalence in the United States which is leading to the growth of the market. The Asia-Pacific is also expected to show a strong growth pattern in the coming years, with China and India showing a rapid progress.
Key Developments in the Market
• May 2017: Novigenix signed a distribution agreement with Dr. Risch Medical Laboratory to access the Swiss German market for colox, its blood based colorectal cancer test
Major Players: ABBOTT DIAGNOSTICS, NOVIGENIX, ALERE, BECKMAN COULTER, CLINICAL GENOMICS, COMPANION DX, EDP BIOTECH, EPIGENOMICS AG, SIEMENS HEALTHCARE, QUEST DIAGNOSTICS, METABIOMICS CORPORATION, AND VOLITION RX, amongst others.
Reasons to Purchase this Report
• Current and future colorectal cancer diagnostics and therapeutics market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• Analysis on the segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
